US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Roche and Vir add to the conflicting Covid-19 data
A win for Vir’s late-to-the-game antibody and another fail for Roche with Actemra show how developers are still feeling their way in Covid-19.
The bull case for Vir starts to unravel
Hopes for the highly valued biotech’s Covid-19 antibody dim before a more important look at the project’s potential.
Pandemic mutations prompt antibody collaborations
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.
Vir becomes a biotech bubble poster child
The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.
Toxicity concerns now hit the Covid antibody approach
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
Two Covid-19 antibodies look better than one for Lilly
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.
